Cargando…

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)

BACKGROUND/AIMS: Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on increasing physician adherence to oral anticoagulant (OAC) guidelines; however, the high early discontinuation rate of vitamin K antagonists (VKAs) is a limitation. Although non-VKA OACs (NOACs) are m...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyeongsoo, Lee, Young Soo, Kim, Tae-Hoon, Cha, Myung-Jin, Lee, Jung Myung, Park, Junbeom, Park, Jin-Kyu, Kang, Ki-Woon, Shim, Jaemin, Uhm, Jae-Sun, Park, Hyung Wook, Choi, Eue-Keun, Kim, Jin-Bae, Kim, Changsoo, Kim, Jun, Joung, Boyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960047/
https://www.ncbi.nlm.nih.gov/pubmed/31014064
http://dx.doi.org/10.3904/kjim.2017.415
_version_ 1783487705091407872
author Kim, Hyeongsoo
Lee, Young Soo
Kim, Tae-Hoon
Cha, Myung-Jin
Lee, Jung Myung
Park, Junbeom
Park, Jin-Kyu
Kang, Ki-Woon
Shim, Jaemin
Uhm, Jae-Sun
Park, Hyung Wook
Choi, Eue-Keun
Kim, Jin-Bae
Kim, Changsoo
Kim, Jun
Joung, Boyoung
author_facet Kim, Hyeongsoo
Lee, Young Soo
Kim, Tae-Hoon
Cha, Myung-Jin
Lee, Jung Myung
Park, Junbeom
Park, Jin-Kyu
Kang, Ki-Woon
Shim, Jaemin
Uhm, Jae-Sun
Park, Hyung Wook
Choi, Eue-Keun
Kim, Jin-Bae
Kim, Changsoo
Kim, Jun
Joung, Boyoung
author_sort Kim, Hyeongsoo
collection PubMed
description BACKGROUND/AIMS: Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on increasing physician adherence to oral anticoagulant (OAC) guidelines; however, the high early discontinuation rate of vitamin K antagonists (VKAs) is a limitation. Although non-VKA OACs (NOACs) are more convenient to administer than warfarin, their lack of monitoring may predispose patients to nonpersistence. We compared the persistence of NOAC and VKA treatment for AF in real-world practice. METHODS: In a prospective observational registry (COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 7,013 patients with nonvalvular AF (mean age 67.2 ± 10.9 years, women 36.4%) were consecutively enrolled between June 2016 and June 2017 from 10 tertiary hospitals in Korea. This study included 3,381 patients who started OAC 30 days before enrollment (maintenance group) and 572 patients who newly started OAC (new-starter group). The persistence rate of OAC was evaluated. RESULTS: In the maintenance group, persistence to OAC declined during 6 months, to 88.3% for VKA and 95.5% for NOAC (p < 0.0001). However, the persistence rate was not different among NOACs. In the new-starter group, persistence to OAC declined during 6 months, to 78.9% for VKA and 92.1% for NOAC (p < 0.0001). The persistence rate was lower for rivaroxaban (83.7%) than apixaban (94.6%) and edoxaban (94.1%, p < 0.001). In the new-starter group, diabetes, valve disease, and cancer were related to nonpersistence of OAC. CONCLUSIONS: Nonpersistence was significantly lower with NOAC than VKA in both the maintenance and new-starter groups. In only the new-starter group, apixaban or edoxaban showed higher persistence rates than rivaroxaban.
format Online
Article
Text
id pubmed-6960047
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-69600472020-01-22 A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Kim, Hyeongsoo Lee, Young Soo Kim, Tae-Hoon Cha, Myung-Jin Lee, Jung Myung Park, Junbeom Park, Jin-Kyu Kang, Ki-Woon Shim, Jaemin Uhm, Jae-Sun Park, Hyung Wook Choi, Eue-Keun Kim, Jin-Bae Kim, Changsoo Kim, Jun Joung, Boyoung Korean J Intern Med Original Article BACKGROUND/AIMS: Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on increasing physician adherence to oral anticoagulant (OAC) guidelines; however, the high early discontinuation rate of vitamin K antagonists (VKAs) is a limitation. Although non-VKA OACs (NOACs) are more convenient to administer than warfarin, their lack of monitoring may predispose patients to nonpersistence. We compared the persistence of NOAC and VKA treatment for AF in real-world practice. METHODS: In a prospective observational registry (COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 7,013 patients with nonvalvular AF (mean age 67.2 ± 10.9 years, women 36.4%) were consecutively enrolled between June 2016 and June 2017 from 10 tertiary hospitals in Korea. This study included 3,381 patients who started OAC 30 days before enrollment (maintenance group) and 572 patients who newly started OAC (new-starter group). The persistence rate of OAC was evaluated. RESULTS: In the maintenance group, persistence to OAC declined during 6 months, to 88.3% for VKA and 95.5% for NOAC (p < 0.0001). However, the persistence rate was not different among NOACs. In the new-starter group, persistence to OAC declined during 6 months, to 78.9% for VKA and 92.1% for NOAC (p < 0.0001). The persistence rate was lower for rivaroxaban (83.7%) than apixaban (94.6%) and edoxaban (94.1%, p < 0.001). In the new-starter group, diabetes, valve disease, and cancer were related to nonpersistence of OAC. CONCLUSIONS: Nonpersistence was significantly lower with NOAC than VKA in both the maintenance and new-starter groups. In only the new-starter group, apixaban or edoxaban showed higher persistence rates than rivaroxaban. The Korean Association of Internal Medicine 2020-01 2019-04-25 /pmc/articles/PMC6960047/ /pubmed/31014064 http://dx.doi.org/10.3904/kjim.2017.415 Text en Copyright © 2020 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Hyeongsoo
Lee, Young Soo
Kim, Tae-Hoon
Cha, Myung-Jin
Lee, Jung Myung
Park, Junbeom
Park, Jin-Kyu
Kang, Ki-Woon
Shim, Jaemin
Uhm, Jae-Sun
Park, Hyung Wook
Choi, Eue-Keun
Kim, Jin-Bae
Kim, Changsoo
Kim, Jun
Joung, Boyoung
A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
title A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
title_full A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
title_fullStr A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
title_full_unstemmed A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
title_short A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
title_sort prospective survey of the persistence of warfarin or noac in nonvalvular atrial fibrillation: a comparison study of drugs for symptom control and complication prevention of atrial fibrillation (code-af)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960047/
https://www.ncbi.nlm.nih.gov/pubmed/31014064
http://dx.doi.org/10.3904/kjim.2017.415
work_keys_str_mv AT kimhyeongsoo aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT leeyoungsoo aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimtaehoon aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT chamyungjin aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT leejungmyung aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT parkjunbeom aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT parkjinkyu aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kangkiwoon aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT shimjaemin aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT uhmjaesun aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT parkhyungwook aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT choieuekeun aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimjinbae aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimchangsoo aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimjun aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT joungboyoung aprospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimhyeongsoo prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT leeyoungsoo prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimtaehoon prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT chamyungjin prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT leejungmyung prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT parkjunbeom prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT parkjinkyu prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kangkiwoon prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT shimjaemin prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT uhmjaesun prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT parkhyungwook prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT choieuekeun prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimjinbae prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimchangsoo prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT kimjun prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf
AT joungboyoung prospectivesurveyofthepersistenceofwarfarinornoacinnonvalvularatrialfibrillationacomparisonstudyofdrugsforsymptomcontrolandcomplicationpreventionofatrialfibrillationcodeaf